MyHealthTeams Co-founders Eric Peacock and Mary Ray
MyHealthTeams, a San Francisco, CA-based creator of the largest and fastest-growing social networks for people facing chronic health conditions raised $9.44 million in a Series B financing round led by strategic investor UCB, a global biopharmaceutical company. This financing brings total investment in MyHealthTeams to $26.84M, building on the company's Seed and Series A1, A2 and A3 rounds. Existing investors including Adams Street Partners,
Read More
IBM, KPMG, Merck and Walmart to Launch FDA Blockchain Pilot Program
IBM, KPMG, Merck, and Walmart today announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a blockchain pilot program in support of the U.S. Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the United States.Pilot Program OverviewThe FDA pilot program is intended to evaluate the use of blockchain technology to assist drug supply
Read More
Biofourmis Lands $35M for AI-Powered Digital Therapeutics Platform
Biofourmis, a Boston, MA-based digital therapeutics platform, today announced that it has raised $35 million in Series B funding led by Sequoia Capital/Sequoia India and co-led by Mass Mutual. The latest funding round will enable the company to advance its proprietary artificialintelligence (AI)-powered digital therapeutics platform and pipeline that treats and manages a range of complex chronic conditions.Digital Therapeutics is Redefining The Healthcare Value ChainFounded in 2015, Biofourmis
Read More
Clinical Operations Makes Highest Use of Artificial Intelligence, Tufts Study Finds
Clinical operations function makes the highest use of artificial intelligence (AI) (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%), according to an analysis recently completed by the Tufts Center for the Study of Drug Development. The analysis, summarized in the May/June Tufts CSDD Impact Report, reveals the pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk
Read More
Pfizer & Concerto HealthAI Team Up on Precision Oncology Collaboration
Concerto HealthAI announced a deal
with Pfizer, through which Pfizer will
harness Concerto HealthAI’s eurekaHealth AI platform
and real-world data (RWD) to help identify new and more precise treatment
options as well as accelerate completion times for various outcomes studies. Concerto
HealthAI is comprised of the leading healthcare data scientists, health
economists, epidemiologists, and AI software engineers to advance flexible and
increasingly enterprise grade solutions for advancing RWE into
Read More
RDMD Lands $3M to Drive Patient-Accelerated Drug Development in Rare Diseases
San Francisco-based RDMD, a biopharma startup dedicated to accelerating research for patients with rare diseases, announced its $3 million seed financing backed by Lux Capital and Village Global, whose network of backers include Bill Gates, Mark Zuckerberg, Jeff Bezos, and Reid Hoffman. RDMD has developed a technology platform that generates deep data insights to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to get
Read More
Novartis to Acquire Gene Therapy Provider AveXis for $8.7B in Cash
Novartis announced today that is has entered into an agreement to acquire AveXis, Inc., a clinical stage gene therapy company for $8.7 billion in cash. AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable healthcare costs. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.The US Food
Read More
Ferring Acquires Microbiome Platform Rebiotix
Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group has acquired Rebiotix Inc., a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to transform the treatment of challenging diseases. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. Rebiotix’s RBX2660 is a non-antibiotic treatment in
Read More
Boston Children’s, TriNetX Bring Data-Driven Approach to Clinical Research
Boston Children’s Hospital has joined the TriNetX global health research network to further its efforts at bringing a more data-driven approach to clinical research. The trend in the healthcare industry is to gain access to a wider pool of patient data in an effort to accelerate the study start-up process and identification of patients for clinical trials. Boston Children’s Hospital is live on the network, as of February 1, 2018.TriNetX is the global health research network that enables
Read More
TriNetX Develops Algorithm for Deducing The Chemotherapy Line of Treatment
TriNetX, the global health research network representing nearly 100 million patients, has developed a groundbreaking chemotherapy lines of treatment identification algorithm that understands treatment patterns to deduce the line of chemotherapy treatment a patient is undergoing. This information, up to now nearly impossible to obtain, is critical for biopharmaceutical companies striving to develop therapies for patients involved in care regimens beyond first line treatments.Chemotherapy lines
Read More